Skip to main content Skip to footer

Agile Press release: Two new therapies to be tested in ground-breaking COVID-19 clinical trial

The trial will be funded by over £3m of investment from GlaxoSmithKline and Vir Biotechnology

GlaxoSmithKline and Vir Biotechnology have joined forces with researchers from the Universities of Liverpool and Southampton, who are leading an accelerated early phase trials platform to test new treatments for COVID-19. The two monoclonal antibody therapies, VIR-7831 and VIR-7832, will be given to patients who have tested positive for COVID-19 and have mild or moderate symptoms. Pre-clinical studies have already shown that these antibody therapies have promising results in combatting coronavirus infections. The hope is that, by conducting early phase human trials, the researchers will discover whether they could be an effective tool for treating patients with the COVID-19 in the future. Read the complete press release.

Other posts

Case study from @Medidata

Take a look at this case study from @Medidata who are supporting @SouthamptonCTU with the AGILE clinical trial platform #COVID19 #clinicaltrials
Read More

Covid-19 Drug interactions

The Liverpool Drug Interactions website team developed a freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents…
Read More